Valuation: Arcutis Biotherapeutics, Inc.

Market Cap 333.34Cr 303.6Cr 279.75Cr 254.47Cr 477.4Cr 31TCr 501.74Cr 3.4TCr 1.35TCr 17TCr 1.25TCr 1.22TCr 53TCr P/E 2026 *
103x
P/E 2027 * 26.8x
Enterprise Value 306.48Cr 279.14Cr 257.21Cr 233.97Cr 438.94Cr 28TCr 461.31Cr 3.13TCr 1.24TCr 16TCr 1.15TCr 1.13TCr 49TCr EV / Sales 2026 *
5.65x
EV / Sales 2027 * 3.88x
Free-Float
98.32%
Yield 2026 *
-
Yield 2027 * -
13/11 Arcutis Says Trial Results Support Zoryve Cream for Infant Dermatitis MT
13/11 Arcutis Biotherapeutics, Inc. Presents Caregiver-Reported Outcomes Data Supporting Zoryve Cream 0.05% for Mild to Moderate Atopic Dermatitis in Infants CI
05/11 Arcutis Biotherapeutics Says First Person Enrolled in Phase 3 Trial of Zoryve to Treat Atopic Dermatitis MT
05/11 Arcutis Biotherapeutics, Inc. Begins Enrolling Phase 3 Study Evaluating ZORYVE Cream 0.3% in Moderate to Severe Atopic Dermatitis CI
05/11 Arcutis Biotherapeutics Insider Sold Shares Worth $1,411,513, According to a Recent SEC Filing MT
05/11 Arcutis Biotherapeutics, Inc., Q3 2026 Earnings Call, Nov 04, 2026
05/11 Earnings Flash (ARQT) Arcutis Biotherapeutics, Inc. Reports Q3 Revenue $143.9M, vs. FactSet Est of $142.6M MT
05/11 Arcutis Biotherapeutics, Inc. Announces Appointment of Rob Lisicki as Chief Commercial Officer, Effective November 4, 2026 CI
05/11 Arcutis Biotherapeutics, Inc. Raises Earnings Guidance for the Full Year 2026 CI
05/11 Arcutis Biotherapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026 CI
28/10 Arcutis Biotherapeutics, Inc. Announces Appointment of Rob Scott as Director and Member of Nominating and Corporate Governance Committee, Effective October 23, 2026 CI
09/10 Arcutis Biotherapeutics, Inc. Presents Data Across Its ZORYVE Portfolio at EADV and Fall Clinical Dermatology Conference CI
09/10 Arcutis Biotherapeutics' Zoryve Shows Rapid Disease Clearance in Infant Atopic Dermatitis Trial MT
1 day-2.98%
1 week-6.72%
Current month-17.80%
1 month-17.29%
3 months+5.10%
6 months+25.46%
Current year-9.23%
1 week 26.28
Extreme 26.285
28.4
1 month 25.23
Extreme 25.23
34.8
Current year 19.3
Extreme 19.295
34.8
1 year 19.3
Extreme 19.295
34.8
3 years 1.76
Extreme 1.76
34.8
5 years 1.76
Extreme 1.76
34.8
10 years 1.76
Extreme 1.76
40.88
Manager TitleAgeSince
Chief Executive Officer 58 01/04/2017
Corporate Officer/Principal 71 03/12/2025
Director of Finance/CFO - 15/05/2025
Director TitleAgeSince
Chairman 55 01/12/2019
Director/Board Member 58 01/01/2016
Director/Board Member 74 01/08/2020
Date Insider Type Main position Quantity % Market Cap. Importance
04/11/26 Exercice

General Counsel

1,20,000 0.0955%
04/11/26 Other

Executive/Senior Manager

2,00,000 0.1591%
02/11/26 Sell

Chief Executive Officer

-4,377 0.0035%
Change 5-day change 1-year change 3-year change Capi.($)
-2.98%-6.72%-10.61%+1,294.71% 333.34Cr
-0.30%-6.68%+27.12%+127.32% 1,20000Cr
+1.25%-5.35%+32.65%+78.98% 65TCr
+0.94%-2.99%+21.13%+106.30% 51TCr
-0.60%-1.95%+25.73%+67.00% 38TCr
+0.69%-9.50%+36.78%+30.83% 33TCr
+0.41%-4.70%+24.18%+50.18% 29TCr
+0.81%-4.08%-2.95%+31.59% 27TCr
-0.15%-6.45%+29.06%+65.76% 24TCr
-0.06%-0.98%+31.42%+122.83% 21TCr
Average +0.00%-4.95%+21.45%+197.55% 41TCr
Weighted average by Cap. +0.30%-5.19%+25.99%+88.87%

Financials

2026 *2027 *
Net sales 54Cr 49Cr 46Cr 41Cr 78Cr 5.02TCr 82Cr 553.77Cr 220.1Cr 2.74TCr 203.42Cr 199.13Cr 8.61TCr 70Cr 64Cr 59Cr 54Cr 100.68Cr 6.51TCr 105.82Cr 718.07Cr 285.4Cr 3.56TCr 263.77Cr 258.21Cr 11TCr
Net income 3.42Cr 3.11Cr 2.87Cr 2.61Cr 4.89Cr 316.26Cr 5.14Cr 35Cr 14Cr 172.74Cr 13Cr 13Cr 542.12Cr 13Cr 12Cr 11Cr 10Cr 19Cr 1.23TCr 20Cr 136.09Cr 54Cr 673.87Cr 50Cr 49Cr 2.11TCr
Net Debt -27Cr -24Cr -23Cr -21Cr -38Cr -2.49TCr -40Cr -274.32Cr -109.03Cr -1.36TCr -100.76Cr -99Cr -4.26TCr -60Cr -55Cr -51Cr -46Cr -87Cr -5.59TCr -91Cr -616.92Cr -245.19Cr -3.05TCr -226.61Cr -221.83Cr -9.59TCr
Projected Income Statement - Annual - Arcutis Biotherapeutics, Inc.
Logo Arcutis Biotherapeutics, Inc.
Arcutis Biotherapeutics, Inc. is a commercial-stage medical dermatology company. The Company develops therapies against biologically validated targets and produces a pipeline for a range of inflammatory dermatological conditions. Its portfolio consists of topical and systemic treatments to treat immune-mediated dermatological diseases and conditions. Its product portfolio includes ZORYVE Roflumilast Cream, ZORYVE Roflumilast Foam, and ARQ-234. The ZORYVE Roflumilast Cream is used for the treatment of seborrheic dermatitis in individuals aged 9 years and older. The ZORYVE Roflumilast Foam for the topical treatment of mild to moderate atopic dermatitis in adults and pediatric patients 6 years of age and older. The ARQ-234 is a fusion protein that is a checkpoint agonist of the CD200 Receptor (CD200R). CD200R is an immune-regulatory receptor which is an immunological checkpoint with a role in the maintenance of immune tolerance.
Employees
354
Date Price Change Volume
20/26/20 $26.36 -2.98% 12,90,169
19/26/19 $27.17 -1.59% 13,30,792
18/26/18 $27.61 +1.02% 8,37,679
17/26/17 $27.33 +0.66% 13,15,543
16/26/16 $27.15 -3.93% 17,01,591
Trader
Investor
Global
Quality
ESG MSCI
BBB
MarketScreener Ratings - Arcutis Biotherapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
26.36USD
Average target price
40.38USD
Spread / Average Target
+53.17%
  1. Stock Market
  2. Stocks
  3. ARQT Stock